On October 31, the U.S. District Court for the Eastern District of Virginia granted a preliminary injunction blocking the U.S. Patent Office’s Claims and Continuations Rules from taking effect. While the rules are on hold, nutraceutical companies need to remain informed so they can make decisions that will maximize the value of their patent portfolios during these uncertain times. In her byline on www.nutraingredients-usa.com, Foley’s Courtenay Brinckerhoff highlights some of the arguments by Smithkline Beecham Corporation (GSK), who challenged the court on the rules, as well as the court’s decisions and the possible impact on nutraceutical companies
